Progenics Pharmaceuticals Progenics is
a biopharmaceutical company focusing on the development and commercialization
of innovative therapeutic products to treat the unmet medical needs of patients
with debilitating conditions and life-threatening diseases. Their principal programs
are directed toward symptom management and supportive care, human immunodeficiency
virus, or HIV,
infection and cancer. They have five product candidates in clinical development
and several others in preclinical development. Their product candidate
in the area of symptom management and supportive care is methylnaltrexone,
or MNTX, a compound in pivotal phase 3 clinical testing. MNTX is designed
to treat the debilitating side effects of narcotic-based pain relievers, which
are referred to as opioid analgesics, without interfering with pain relief.
MNTX -- Advanced medical ilness, post-operative
ileus, chronic pain GMX -- Melanoma
Cancer PSMA -- Prostate
cancer PRO542 -HIV PRO 140 HIV More About Progenics